1. Scrip
  2. >>Leadership
  3. >>Executives On The Move

Exscientia Focus Firmly On Pipeline After CEO Exit Scandal

 
• By Kevin Grogan

The sacking of CEO Andrew Hopkins over inappropriate relationships with two employees has cast a cloud over the high-profile AI biotech.

Andrew Hopkins
Andrew Hopkins • Source: Exscientia

The lights have dimmed at one of the brightest stars in UK biotech as the artificial intelligence specialist Exscientia plc faces up to the fallout from the sacking of founder and CEO Andrew Hopkins over “inappropriate” relationships with two members of staff.

Shares in the NASDAQ-listed Oxford-based group slumped nearly 23% to $5.80 on 13 February after Exscientia revealed in a US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Executives On The Move

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

Executives On The Move: Three New CEOs And CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

More from Leadership